ID   BE(2)-C/ADR(5)
AC   CVCL_V006
SY   Be2-C/ADR5; Be2C/ADR5
DR   cancercelllines; CVCL_V006
DR   Cosmic; 922660
DR   Wikidata; Q54795863
RX   PubMed=8665486;
RX   PubMed=15390183;
CC   Population: Caucasian.
CC   Characteristics: Intermediate type (I-type) (from parent cell line).
CC   Characteristics: MYCN-amplified NBL cell line (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0529 ! SK-N-BE(2)-C
SX   Male
AG   2Y2M
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 18
//
RX   PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4;
RA   Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.;
RT   "The p16 and p18 tumor suppressor genes in neuroblastoma: implications
RT   for drug resistance.";
RL   Cancer Lett. 104:183-192(1996).
//
RX   PubMed=15390183; DOI=10.1002/gcc.20096;
RA   Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.;
RT   "Expression profiles and clinical relationships of ID2, CDKN1B, and
RT   CDKN2A in primary neuroblastoma.";
RL   Genes Chromosomes Cancer 41:297-308(2004).
//